Drug Manufacturing

Etana to launch Innovent Biologics’ cancer drug BYVASDA in Indonesia

Chinese pharmaceutical company Innovent Biologics has signed an out-license agreement with Etana Biotechnologies to develop and commercialise cancer drug BYVASDA (Bevacizumab Biosimilar) in Indonesia.

Thermo Fisher Scientific acquires viral vector business from Novasep for $875m

Thermo Fisher Scientific announced the acquisition of Henogen, a Belgian viral vector manufacturing business belonging to Groupe Novasep, for about €725m ($875m) in cash.

Fujifilm to invest $2bn to build large-scale cell culture manufacturing site in US

Fujifilm is set to invest about $2bn to build a new large-scale cell culture production site for biopharmaceuticals in the US.

Symbiosis and AstraZeneca sign supply agreement for sterile manufacture of Covid-19 vaccine for clinical trials

Symbiosis Pharmaceutical Services, a specialist provider of pharmaceutical and vaccine development services, has announced it has signed a supply agreement with AstraZeneca for sterile manufacture of the Covid-19 recombinant adenovirus vaccine known as AZD1222 for AstraZeneca sponsored clinical trials.

Novo Nordisk agrees to acquire Corvidia Therapeutics for $2.1bn

Novo Nordisk has agreed to acquire Corvidia Therapeutics, a portfolio company of life sciences venture capital firm Sofinnova Partners, in a deal valued at $2.1bn.

BioCryst bags contract to supply RAPIVAB antiviral flu therapy doses to CDC

BioCryst Pharmaceuticals has secured a $34.7m contract from the US Centers for Disease Control and Prevention (CDC) for the supply of up to 50,000 doses of its approved antiviral influenza therapy, RAPIVAB (peramivir injection) over a five-year period.

Aurobindo to buy parts of Sandoz US from Novartis for $900m

Aurobindo Pharma USA has agreed to acquire selected portions of Sandoz US portfolio from Novartis for $900m of cash and $100m of potential earn-outs.

EUSA Pharma to buy global rights of Janssen’s Sylvant for $115m

UK-based EUSA Pharma has agreed to acquire the global rights of Sylvant (siltuximab), a rare blood disorder drug, from Janssen Sciences Ireland UC for $115m.

Clinigen acquires global rights to Proleukin outside US

Clinigen Group has acquired the global rights to Proleukin (aldesleukin, recombinant interleukin-2) outside the United States from Novartis.